ArticleEuropean journal of neurology2021
Multiple sclerosis and COVID-19: How many are at risk?
Article in European journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.Journal of neurology · 2025Article
- Characteristics and Outcomes of 7620 Multiple Sclerosis Patients Admitted With COVID-19 in the United States.The Neurohospitalist · 2024Article
- Prognostic indicators for hospitalization and ICU admission in people with multiple sclerosis and COVID-19: an analysis of the COVID-19 in MS global data sharing initiative dataset.Annals of medicine and surgery (2012) · 2024Article
- Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo.Medical science monitor : international medical journal of experimental and clinical research · 2024Observational
- The IMPACT of the COVID-19 Pandemic on Prescription Drug Use in Patients with Psoriasis Vulgaris in Germany.Dermatology and therapy · 2023Article
- COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece.Journal of clinical medicine · 2023Article
- Impact of vaccination on COVID-19 outcome in multiple sclerosis.European journal of neurology · 2022Article
- Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.European journal of neurology · 2022Article
- Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.Journal of neurology · 2022Article
- Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.Frontiers in immunology · 2022Review
- Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha.Frontiers in oncology · 2022Review
- Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.Multiple sclerosis and related disorders · 2021Article
- Administration of COVID-19 vaccines in immunocompromised patients.International immunopharmacology · 2021Review
- Multiple sclerosis and COVID-19: How many are at risk?European journal of neurology · 2021Article
- Impact of the COVID-19 pandemic on access to healthcare services amongst patients with multiple sclerosis in the Lazio region, Italy.European journal of neurology · 2021Article
- The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.Biomolecules · 2021Review
- Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.Molecular neurobiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe coronavirus disease 2019 (COVID-19) pandemic challenges neurologists in counseling multiple sclerosis (MS) patients with respect to their risk for and by severe acute respiratory syndrome coronavirus 2 and in guiding disease-modifying treatment (DMT). The objective was to determine the frequency and distribution of currently known risk factors for COVID-19 mortality in an MS population.
methodsMultiple sclerosis patients with at least one complete case report between January 1, 2015 and December 31, 2019 from the Innsbruck MS database were cross-sectionally included. Frequencies of currently estimated COVID-19 mortality risk factors were analyzed, and the cumulative risk was calculated by a recently developed score. For every risk group, the proportions of patients under DMT and immunosuppressive treatment were determined.
resultsOf 1931 MS patients, 63.4% had low risk of COVID-19 mortality, 26% had mild risk, 8.8% had a moderate risk, whereas a combined 0.9% had high or very high risk of COVID-19 mortality. Of the patients at high or very high risk, only one patient received DMT and none had an immunosuppressive therapy.
conclusionsIn a population-based MS cohort, the proportion of patients at high risk of COVID-19 mortality is below 1%. Importantly, the vast majority of these MS patients did not receive any DMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.